Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.80 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL11766349 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL29424258 | 0.95 | CA1 (0.73) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL4346332 | 0.95 | CA1 (0.73) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL28859803 | 0.95 | CA1 (0.82) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL11768103 | 0.95 | CA1 (0.82) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL586756 | 0.95 | CA1 (0.89) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL27628723 | 0.95 | CA1 (0.89) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL23872 | 0.95 | — | — | |
| Acetic Acid SCHEMBL2407889 | 0.95 | CA1 (0.89) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL7594137 | 0.91 | CA1 (0.75) | CA1CA4LMNATSHRFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288416-B2 | Substituted piperidinophenyl oxazolidinones | WOCKHARDT LTD. (IN) | 2012-10-16 | — | — | US | disclosed |
| EP-2069339-B1 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | WOCKHARDT RESEARCH CENTER (IN) | 2011-05-18 | — | — | EP | disclosed |
| US-20100120721-A1 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | WOCKHARDT RESEARCH CENTRE (IN) | 2010-05-13 | — | — | US | disclosed |
| EP-2069339-A2 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | Wockhardt Research Centre (IN) | 2009-06-17 | — | — | EP | disclosed |
| EP-1940316-A2 | PRESSURE ATTENUATION DEVICE | Solace Therapeutics, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007038476-A9 | PRESSURE ATTENUATION DEVICE | ATTENEUX TECHNOLOGIES INC (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038092-A2 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | WOCKHARDT RESEARCH CENTRE (IN) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007038476-A2 | PRESSURE ATTENUATION DEVICE | ATTENEUX TECHNOLOGIES, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| EP-0837703-A4 | APPARATUS FOR CONTROLLED FLUID DELIVERY | RIVER MEDICAL INC (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0837703-A1 | APPARATUS FOR CONTROLLED FLUID DELIVERY | RIVER MEDICAL, INC. (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997002849-A1 | APPARATUS FOR CONTROLLED FLUID DELIVERY | RIVER MEDICAL, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
| EP-0748252-A1 | GAS DELIVERY APPARATUS AND COMPOSITIONS FOR INFUSION | RIVER MEDICAL, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023641-A1 | GAS DELIVERY APPARATUS AND COMPOSITIONS FOR INFUSION | RIVER MEDICAL, INC. (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120721-A1 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | CYP2C19, ALPI, CYP3A7 | CA1 4512/4885CA4 2300/4885LMNA 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.